Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. - Wikidata - awgldk - TriplyDB

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

http://www.wikidata.org/entity/Q44028935

about

Antipsychotics in the treatment of autism Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses Aripiprazole versus placebo for schizophrenia Aripiprazole versus placebo for schizophrenia Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities Brexpiprazole: so far so good The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis Aripiprazole for treating irritability in children & adolescents with autism: A systematic review Emerging pharmacologic treatment options for fragile X syndrome Review of depot aripiprazole for schizophrenia When to start aripiprazole therapy in patients with bipolar mania Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future Dopamine receptor activation increases HIV entry into primary human macrophages Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats In Vitro and In Vivo Characterization of the Alkaloid Nuciferine Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C Animal Models of Psychosis: Current State and Future Directions.Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.How antipsychotics work-from receptors to reality.Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Aripiprazole Facilitates Extinction of Conditioned Fear in Adolescent Rats.Effect of aripiprazole on non-24-hour sleep-wake rhythm disorder comorbid with major depressive disorder: a case report.Resolution of Ziprasidone-Related Tardive Dyskinesia With a Switch to Aripiprazole Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.Classics in Chemical Neuroscience: Aripiprazole.

P2860

Q22241891-EB33C067-4C4F-484C-A9BE-361E836B0D9E Q23913269-7AAC4538-AC8B-46F6-9B66-C958D86FE196 Q24186218-66725B78-0EC1-4972-B2A7-B7E58F5D4AD6 Q24186219-EF2D8BA1-3680-44FD-809A-4F7EA6193CC6 Q24186220-E4FD663E-F6B7-4D00-AB5F-CAAABD769723 Q24186223-E6BCA4E5-9955-4CCC-8FA5-7F472C714EBA Q24234961-2E060B60-F57A-4829-A086-48105B8D5780 Q24244718-68875F22-11A2-4369-A566-87EBE465DB6C Q24615556-435627E1-8772-4DFF-B92B-FC3A8B5147D3 Q26766401-9F65BF30-DC4C-471D-AD6C-3120875AC5A1 Q26782978-A9D3AC05-0C84-4202-944F-D6C57893D4C7 Q26784199-FD8B0C0E-7FA7-4E08-8C81-89AA31292067 Q26829152-B883A0D3-04BA-4744-AFDE-1CF664C571CF Q27008464-A631054D-393F-45C9-A355-D43401526892 Q27014860-5B2F0CF7-C357-4543-A0D4-A9C0E2D3858B Q28076943-2D5479BC-FA42-4C0C-B753-B36BA045DC63 Q28084069-302D02C0-114D-4F79-AD00-71084714FA3E Q28273912-63D9D014-F48A-4954-B685-AECA9F741903 Q28394341-B63397C0-B53D-42F6-AC00-D5FB6FAED0CB Q28543414-9F7D39E3-3423-4582-B545-7500BAA331B5 Q28546441-5B523C88-8913-4CF5-B0C4-5AFC2D67FDB5 Q28550683-D1C32F4A-779C-4FFA-8C2D-4B76F25DA58C Q28577651-C3665248-25EE-4C89-81D2-91573B15B676 Q28972478-F01B2C6C-1C14-4CC5-B2D7-FA7CBA3BBD0C Q30400003-B486482E-0495-4853-AAC3-22EA3E933486 Q30410153-87D6BD81-B269-4D2C-A491-B1CA173FE0AB Q30411445-64ECA304-F70D-489F-9228-F55D2DA1F4B1 Q30457477-7B416955-F0B2-44A8-AB28-834D77136E07 Q30459211-CFEBD198-43EE-4AF2-A034-8F06A6EA97DC Q33518314-BA89D8A9-27D5-44F8-BC48-E19D547687EF Q33587032-75D505CF-E898-4E8C-92B6-7363F2744499 Q33614458-6C5FDE99-8C17-4484-B865-DCAD8424434A Q33650040-E896DF30-843C-49BA-A223-43E0701DB7B4 Q33739852-2A5854F7-CF81-4A03-8BE8-6ABEA4F8FB18 Q33740419-E28E40BC-83F1-4224-A287-B2F2502A77EE Q33755676-6EB5F06E-05EE-481F-A938-DF972E56ABC8 Q33799660-7CE41FFB-9390-4B71-BA4D-56269882C931 Q33841432-D72C8C33-BEE0-401C-887F-AC34C464484D Q33858314-F2CD2ACB-45DD-49AB-96F1-7A48BDCF7B5F Q33866125-9DCADFBD-9DCA-4C18-BDDB-C8C3AE0C06C2

P2860

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

http://www.wikidata.org/entity/Q44028935

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@en

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@nl

type

label

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@en

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@nl

prefLabel

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@en

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@nl

P1433

Q44028935-46F0854C-F7C9-435F-AA02-6D8D6BEB98FB

P1476

Q44028935-4F28D5BE-BF5B-4DA2-84F4-866BE7EE6079

P2093

Q44028935-1246EA9D-CA16-4484-8F07-680CDAB468FD

Q44028935-1B3116CC-31C3-482C-8BF8-BC7CBCF1CF71

Q44028935-287B06F9-4E2B-49AB-A9C0-6D1249332F7D

Q44028935-38FEF87D-CCEB-4ADA-A340-E1DCE98F3719

Q44028935-40AD0128-5268-45B5-92A2-617C2907913B

Q44028935-6743713B-E2D1-4A56-9C97-B851CB41C1DB

Q44028935-DCC3E7C7-C1C9-4D3E-A61C-4C50521EC8D2

Q44028935-E4C7B23F-22A6-4344-B50B-3EFD923D9C80

P304

Q44028935-5168DDF2-A5F3-4F25-8B9A-0320DD5D1BA0

P31

Q44028935-0749C448-DC03-4600-BECB-03694E65C5B7

P356

Q44028935-3818B736-B2DA-41CB-B31F-5721F9DBE739

P407

Q44028935-515837B2-9700-460E-B5BA-5E6EF2152B4E

P433

Q44028935-DF486864-CAC7-4571-8A81-60CA2179AF54

P478

Q44028935-E3227F68-C2C1-4ECF-9AF9-E420A62E20E4

P577

Q44028935-606655EE-9FAC-4D8E-A317-3A6D95A0F847

P5875

Q44028935-02261EC9-3596-4B5E-9C81-48B146FFF815

P698

Q44028935-B43A51F9-A960-4464-A8E6-F65DE1BFA0D8

P921

Q44028935-405fadf2-7f4c-4bc1-8059-0ef446397d95

P356

JPET.102.033175

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Aripiprazole, a novel antipsyc ...... t human dopamine D2 receptors.

@en

P2093

Cen Xu

http://www.w3.org/2001/XMLSchema#string

Elaine Ryan

http://www.w3.org/2001/XMLSchema#string

Frank D Yocca

http://www.w3.org/2001/XMLSchema#string

Katsura Tottori

http://www.w3.org/2001/XMLSchema#string

Kevin D Burris

http://www.w3.org/2001/XMLSchema#string

Perry B Molinoff

http://www.w3.org/2001/XMLSchema#string

Tetsuro Kikuchi

http://www.w3.org/2001/XMLSchema#string

Thaddeus F Molski

http://www.w3.org/2001/XMLSchema#string

P304

381-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.102.033175

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

302

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277515678

http://www.w3.org/2001/XMLSchema#string

P698

12065741

http://www.w3.org/2001/XMLSchema#string

P921